9 / 25
•
ctDNA has emerged as an alternative to tumor biopsy to detect mutations in mCRC.
•
Concordance between
RAS
mt in plasma and tissue is high (90%)
Grasselli et al, Ann Onc 2017
•
Exploratory analysis of this study showed a
shorter OS in mCRC with RAS MAF higher
than 10%.
•
This exploratory analysis was in the whole
population which was very heterogenous
in terms of treatment and moment of the
plasma analysis.
Background